Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at BTIG Research. They set a "buy" rating and a $42.00 price target on the stock.
Cartesian Therapeutics Announces New Employment Inducement Grants
Arthrosi Appoints John Leaman, M.D., to Its Board of Directors [Yahoo! Finance]
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock, up previously from $41.00.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.